Medindia22h
FDA Approves EBGLYSS Drug for Atopic Dermatitis in Adults and Children
EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...
Medical News Today3d
EBGLYSS for eczema: What to know about the newly FDA-approved drug from Eli Lilly
The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...
Medscape12d
FDA Approves Lebrikizumab for Atopic Dermatitis
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...
Medpage Today on MSN13d
Lebrikizumab Wins FDA Approval for Eczema
The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...
Everyday Health9d
Ebglyss, a New Biologic Treatment for Atopic Dermatitis, Gets FDA Approval
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
Le Lézard13d
FDA Approves Lilly's EBGLYSStm (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall S.A. has licensed the rights to develop and ...
Daily13d
FDA Approves lebrikizumab for treatment of atopic dermatitis
The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...
Morningstar13d
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
The most common side effects of EBGLYSS include eye and eyelid inflammation, such as redness, swelling and itching; injection site reactions and shingles (herpes zoster). EBGLYSS cannot be used in ...